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MESALAZINE is widely used in the treatment of inflam-
matory bowel disease. Little is known about the dose-
response  relationship  and  about  possible  dose
related  side effects. In ulcerative colitis higher dos-
ages of mesalazine (3 g) are more effective in main-
taining  a  remission  than  lower  dosages  (1.5 g).  In
mild  to  moderately  active  ulcerative  colitis,  studies
also  indicate  that  higher  dosages  might  be  more
effective  in  inducing  remission.  Dose-comparing
studies in Crohn’s disease are even more sparse, but
the available results indicate higher efficacy at higher
dose levels.
None of the known side effects of mesalazine are
clearly dose-related. A pH-dependent release system,
however, can cause a sudden release of high doses of
mesalazine.  Consequent  peak  levels  in  serum  have
been  implicated  in  mesalazine  induced  nephrotox-
icity.  In conclusion,  despite  the  current  practice  of
using increasing dosages of mesalazine in inflamma-
tory bowel disease, both efficacy and safety have been
established tentatively.
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Introduction
In recent years there has been a series of advances in
the treatment of inflammatory  bowel disease (IBD)
(Crohn’s disease and ulcerative colitis). Sulfasalazine
was introduced into the treatment of IBD by Nana
Swartz in the 1930s.1 It has been demonstrated in the
late 1970s that the therapeutic activity of sulfasalazine
is attributable to the local action of its mesalazine.2
New formulations of mesalazine have been developed
in the 1980s with the aim of achieving liberation of
the drug in the distal small intestine and the colon.3
Commonly  used  dosages  in  IBD  are  1.5–4.8g  in
divided dosages.4 However dose–response relations
are insufficient reported in current literature to give
sufficient guidelines. This article reviews the available
studies for a dose response relation for mesalazine in
IBD.
Mesalazine
Mesalazine  preparations  are  established  as  the  first
line treatment for IBD being effective in the active
disease  state  as  well  as  maintaining  patients  in
remission.4 In  view  of  the  trend for  use  of  higher
doses up to 4–6g per day, it has become a matter of
interest  to  determine  which  side-effects  might  be
connected with  the  use  of  mesalazine. This  means
that patients need to take two 500mg microgranule
tablets (Pentasa) four times per day. However, some
patients cannot readily tolerate this number of tablets
and therefore, a formulation containing 1g of Pentasa
microgranules per sachet has been developed as an
alternative. In a volunteer study gastric emptying and
colon filling rates associated with both formulations,
the old and new, were the same.5 In pH-dependent
formulations like Asacol, Claversal/Salofalk a problem
in increasing the volume of mesalazine per tablet is
the  potential  sudden  release  of  the  entire  higher
dosage of drug contents of the tablet in one area of
the gastrointestinal tract when a pH favouring dissolu-
tion of the coating is encountered. This problem was
illustrated in a pharmacokinetic comparison of Asa-
col, Claversal/Salofalk and Pentasa tablets. Claversal
absorption  was  the  highest  of  all.6 However  more
data about the new delivery systems like Asacol 800
are needed to allow physicians to choose with some
degree of confidence which tablets to use for daily
mesalazine dosages of 4–6g daily.
Dose-dependent Adverse Effects
The  incidence  of  the  common  types  of  adverse
effects  associated  with  sulphasalazine  correlates
closely  to  the  total  sulfapyridine  concentration  in
serum.  The  new  sulfa-free  salicylates  are  better
tolerated  than  sulfasalazine.  Adverse  effects  asso-
ciated  with  mesalazine  include  headache,  fever,
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rhagic  colitis,  diarrhoea,  interstitial  nephritis  and
muscle aches. The adverse effect of mesalazine that
causes  greatest  concern  is  nephrotoxicity.  It  was
suggested that  the interstitial  nephitis is caused by
high  serum  peaks  of  mesalazine.7 Some  suggested
that this can only be reached with the pH-depend-
ent  formulations.  However  we  have  reported  such
side  effect  in a  low  daily dosage  of  1.5g  Pentasa.8
Adequate epidemiological studies must  recognize if
side-effects  like  headache,  fever  etc.  are  dose-
dependent.  Pericarditis  and  pancreatitis  are  prob-
ably not dose-dependent.9,10 We have to realize that
methods of determining adverse events in trials are
rather  artificial,  with  compulsive,  repeated  open-
ended  questioning.  Moreover,  reporting  of  adverse
events  in  journals  is  problamatic  and  gives  no
answer about the frequency or absolute numbers of
side-effects.
Dose–response in Efficacy
Many investigators in the early 1980s believed that the
development of the new mesalazine delivery systems
would allow us to use higher dosages, which might
provide  additional  therapeutic  benefits  to  patients.
However after more than 15 years of investigation of
the  newer  mesalazine  compounds  involving  thou-
sands of patients, clear conclusions about the various
dosages cannot be made.
For sulfasalazine there is a dose–response relation-
ship for the treatment of quiescent ulcerative colitis.11
In a recent study the group that received a 3g dose of
Pentasa  showed  a  clear  trend  towards  prolonged
remission  in  the  intention  to  treat  analysis,  when
compared with the 1.5g group.8 No other data about
ulcerative colitis in remission-maintaining studies and
dose–response  are  available.  In  1987  Schroeder  et
al.14 studied the efficacy and safety of Asacol in the
treatment  of  mildly to  moderately  active  ulcerative
colitis. With 1.6g versus 4.8g pH-dependent mesala-
zine tablet (Asacol) results showed 24% complete and
50% partial responses in those patients receiving 4.8g
of mesalazine per day compared with 5%  complete
and 13% partial responses in those receiving placebo
(P <  0.0001).  At  a  dosage  of  1.6g  per  day,  the
response  was  twice  as  good  as  placebo,  but  the
difference  did  not  reach  statistical  significance.
Recently  these  results  have  been  confirmed  with
Pentasa.12 The 2g and 4g mesalazine doses produced
significant endoscopic improvement compared with
placebo (P < 0.004). Only the 4g dose produced a
significant  histologic  improvement  compared  with
the placebo (P < 0.002).
Only  one  study  found  a  statistically  significant
beneficial therapeutic effect of mesalazine in Crohn’s
disease at a dose of 4g/day compared with 1–2g/day
and placebo.13 However no other data about dose–
response studies in Crohn’s disease are available.
Conclusion
More  and  more  investigators  focus  on  therapeutic
stratergies  that  target  the  recently  characterized
inflammatory  mediators  in  IBD.  Unfortunately  the
questions of the 1980s have not been answered. For
instance, is one mesalazine preparation better than
others?  What  is  the  appropriate  dose  for  optimal
treatment with oral preparations? Some investigators
concentrate  on  meta-analysis  studies  in  order  to
define the role and efficacy of mesalazine, however
only  prospective  randomized  controlled  trials  can
answer all these questions. For many patients mesala-
zine  makes a  significant  difference  to  their  disease
activity and quality of life. To our knowledge only one
dose–response  study  will  be  presented  within  the
next years about this issue, comparing 1.6 versus 3.2
Asacol and 3g Claversal/Salofalk. Unfortunately these
questions of the past will not be answered in the near
future.
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